The BLF Early COPD Development Partnership Grant
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03480347|
Recruitment Status : Recruiting
First Posted : March 29, 2018
Last Update Posted : March 29, 2018
Most existing medical research has focused on patients with well-established COPD and poor lung function. Whilst this is important because such patients have lots of symptoms and problems, in some respects a better way of reducing health problems in the future would be to develop a strategy which focuses on patients with milder disease, and identifies which ones will go on to develop more severe problems and why these problems occur. The research in this application is designed to investigate these issues.
The main objective of the Partnership is to study the very early stages of the development of COPD. The investigators will do this by recruiting a novel cohort of smokers (age 30-45), in whom the investigators will follow the trajectories of lung function decline to identify prospectively those at risk of excess decline. This programme forms a unique UK consortium of 8 academic centres with excellent high quality publication records and broad experience in mechanistic, translational, clinical and epidemiological studies in COPD with key capabilities including primary care.
|Condition or disease|
|Chronic Obstructive Pulmonary Disease|
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||The BLF Early COPD Development Partnership Grant|
|Actual Study Start Date :||January 17, 2018|
|Estimated Primary Completion Date :||September 3, 2020|
|Estimated Study Completion Date :||September 3, 2020|
- Annual change in lung function [ Time Frame: Three years ]assessed by post-bronchodilator at 6 monthly intervals over a 3 year period.
- Annual change in lung function [ Time Frame: Three years ]assessed by body box plethysmography at 6 monthly intervals over a 3 year period.
- Lung tissue attenuation and airway dimensions [ Time Frame: Three years ]determined by CT-Scanning
- Lung tissue attenuation and airway dimensions [ Time Frame: Three years ]Assessed by full blood and differential counts
- Lung tissue attenuation and airway dimensions [ Time Frame: Three years ]Assessed by prevalence of chronic bronchitis as determined by MRC Bronchitis Questionnaire
- Lung tissue attenuation and airway dimensions [ Time Frame: Three years ]Assessed by respiratory symptoms, as determined by CAT Questionnaire
- Lung tissue attenuation and airway dimensions [ Time Frame: Three years ]Assessed by dyspnoea as determined by MRC Dyspnoa Scale
- Lung tissue attenuation and airway dimensions [ Time Frame: Three years ]Assessed by respiratory infections as determined by Respiratory Infection Questionnaire
- Lung tissue attenuation and airway dimensions [ Time Frame: Three years ]Assessed by depression and anxiety as determined by Hospital Anxiety Depression Scale
Biospecimen Retention: Samples With DNA
- Blood samples will be collected to determine full Blood count,. Blood serum, plasma and a blood pellet (DNA) will be stored for further analysis of markers of inflammation and infection.
- Sputum samples (either spontaneous or induced) will be collected and stored and used for microbiome studies, inflammatory markers, and pathogen detection.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03480347
|Contact: Ethaar El-Emir, PhD||+44 (0)20 7594 firstname.lastname@example.org|
|Contact: Gavin Donaldson, PhD||0207 594 email@example.com|
|Royal Brompton and Harefield NHS Foundation Trust||Recruiting|
|London, United Kingdom|
|Contact: Ethaar El-Emir|